MX2016010662A - Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos. - Google Patents

Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.

Info

Publication number
MX2016010662A
MX2016010662A MX2016010662A MX2016010662A MX2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A MX 2016010662 A MX2016010662 A MX 2016010662A
Authority
MX
Mexico
Prior art keywords
humans
compounds
neurological disorders
social behavior
improving cognition
Prior art date
Application number
MX2016010662A
Other languages
English (en)
Inventor
Shamloo Mehrdad
Yi Bitna
Memar Ardestani Pooneh
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Publication of MX2016010662A publication Critical patent/MX2016010662A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un compuesto de profármaco agonista de ß1-ADR, el cual es hidrolizable in vivo para liberar un compuesto agonista de ß1-ADR, y en el cual el compuesto de profármaco contiene un grupo el cual imparte mayor lipofilicidad y biodisponibilidad al CNS al compuesto de profármaco con relación al compuesto agonista de ß1-ADR.
MX2016010662A 2014-02-18 2015-02-18 Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos. MX2016010662A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461940980P 2014-02-18 2014-02-18
PCT/US2015/016340 WO2015126915A2 (en) 2014-02-18 2015-02-18 Method of improving cognition and social behavior in humans having deficits therein due to neurological disorders and compounds and compositions therefor

Publications (1)

Publication Number Publication Date
MX2016010662A true MX2016010662A (es) 2017-04-27

Family

ID=53879228

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010662A MX2016010662A (es) 2014-02-18 2015-02-18 Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.

Country Status (8)

Country Link
US (1) US9849134B2 (es)
EP (1) EP3122350A4 (es)
JP (1) JP2017505826A (es)
KR (1) KR20170013856A (es)
CN (1) CN106456649A (es)
CA (1) CA2940059A1 (es)
MX (1) MX2016010662A (es)
WO (1) WO2015126915A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11173144B2 (en) 2016-05-13 2021-11-16 The Board Of Trustees Of The Leland Stanford Junior University Adrenergic receptor modulating compounds and methods of using the same
CA3161376A1 (en) 2019-12-18 2021-06-24 Anthony P. FORD Methods for improving neurological diseases and disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3270905D1 (en) * 1981-12-17 1986-06-05 Haessle Ab Para-substituted 3-phenoxy-1-carbonylaminoalkylamino-propan-2-ols having beta receptor blocking properties
GB8529885D0 (en) 1985-12-04 1986-01-15 Ici Plc Therapeutic agent
AU2061588A (en) * 1987-09-07 1989-03-09 Imperial Chemical Industries Plc Phenol ester of xamoterol
US6043224A (en) 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
JP2004509920A (ja) 2000-09-29 2004-04-02 ボード　オブ　トラスティーズ　オペレーティング　ミシガン　ステート　ユニヴァーシティ カテコールアミン医薬組成物および方法
WO2004080283A2 (en) 2003-03-07 2004-09-23 The Trustees Of Columbia University, In The City Of New York Type 1 ryanodine receptor-based methods
US20050096311A1 (en) 2003-10-30 2005-05-05 Cns Response Compositions and methods for treatment of nervous system disorders
US8470546B2 (en) 2008-11-25 2013-06-25 Albert Einstein College Of Medicine Of Yeshiva University Treatment of autism spectrum disorders with agents that activate the Locus Coeruleus-Noradrenergic system
EP2370076B1 (en) * 2008-11-28 2017-01-04 Novartis AG Pharmaceutical combination comprising a Hsp 90 inhibitor and a mTOR inhibitor
US9072730B2 (en) * 2009-05-14 2015-07-07 The Board Of Trustees Of The Leland Stanford Junior University Method of improving cognitive functions in individuals with down syndrome and/or alzheimer's disease
RU2570424C2 (ru) 2009-12-15 2015-12-10 МЕТАБОЛИК СОЛЮШНЗ ДЕВЕЛОПМЕНТ КОМПАНИ, ЭлЭлСи Рапп-поддерживающие тиазолидиндионы и их комбинации для лечения нейродегенеративных заболеваний

Also Published As

Publication number Publication date
CN106456649A (zh) 2017-02-22
US9849134B2 (en) 2017-12-26
WO2015126915A2 (en) 2015-08-27
WO2015126915A3 (en) 2015-11-19
CA2940059A1 (en) 2015-08-27
JP2017505826A (ja) 2017-02-23
US20160184315A1 (en) 2016-06-30
KR20170013856A (ko) 2017-02-07
EP3122350A2 (en) 2017-02-01
EP3122350A4 (en) 2018-01-10

Similar Documents

Publication Publication Date Title
IL248546A0 (en) A polysubstituted fluorine compound as a proton tyrosine kinase inhibitor
IL289474A (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
PH12016502177A1 (en) Processes of preparing a jak1 inhibitor and new forms thereto
SG11201608764QA (en) Novel disubstituted 1, 2, 4-triazine compound
SV2017005586A (es) Procesos e intermediarios para la preparacion de {1- (etilsulfonil) -3- [4 -(7h -pirrolo [2, 3-d] pirimidin -4- il) -1h -pirazol -1- il] azetidin -3- il} acetonitrilo
HK1258964A1 (zh) 用於製備1，3-苯並間二氧雜環戊烯雜環化合物的方法
PH12017500459A1 (en) Azetidinyloxyphenylpyrrolidine compounds
ZA201608442B (en) Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
ZA201701132B (en) Novel 2,5-substituted pyrimidines as pde inhibitors
MX2018003903A (es) Compuesto biciclico y uso del mismo para inhibicion de suv39h2.
HK1221463A1 (zh) 可用作 抑制劑的新型化合物
HK1256825A1 (zh) 取代的5，6-二氫-6-苯基苯並[f]異喹啉-2-胺化合物的固體形式
GB2556654B (en) Production of alkylated compounds
MX2019004024A (es) Metodo para preparar acetofenonas sustituidas con ciclopropilo.
MX2016010662A (es) Compuestos para mejorar la cognicion y comportamiento social en humanos que tienen trastornos neurologicos.
GB201612872D0 (en) Prodrug compounds
AR101951A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
MX2016013439A (es) Formas solidas de un compuesto farmaceuticamente activo.
PH12017500492A1 (en) Crystalline bace inhibitors
HK1256865A1 (zh) 有機化合物的蓋倫製劑
MX2015011881A (es) Proceso para la preparacion de 3,7-dimetilnonan-1-ol.
IN2013MU04030A (es)
IL264465B (en) Substituted thiazolo-pyridine compounds as malt1 inhibitors
IN2014MU00069A (es)
GB201408238D0 (en) Synthesis of substituted 1,2,3-Triazoles